Back to Search

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)


  • Protocol Number: 201911163
  • Principal Investigator: Stockerl-Goldstein, Keith
  • Cancer Types: Leukemia, Myeloma, and Hematologic

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions